American journal of respiratory and critical care medicine
-
Am. J. Respir. Crit. Care Med. · Nov 2014
Randomized Controlled Trial Multicenter StudyProcalcitonin Algorithm in Critically Ill Adults with Undifferentiated Infection or Suspected Sepsis: A Randomized Controlled Trial.
The role of procalcitonin (PCT), a widely used sepsis biomarker, in critically ill patients with sepsis is undetermined. ⋯ In critically ill adults with undifferentiated infections, a PCT algorithm including 0.1 ng/ml cut-off did not achieve 25% reduction in duration of antibiotic treatment. Clinical trial registered with http://www.anzctr.org.au (ACTRN12610000809033).
-
Am. J. Respir. Crit. Care Med. · Nov 2014
α-Hemolysin Activity of Methicillin-Susceptible S. aureus Predicts Ventilator-Associated Pneumonia.
Colonization of lower airways by Staphylococcus aureus is a risk factor for the development of ventilator-associated tracheobronchitis (VAT) and ventilator-associated pneumonia (VAP). However, little is known about the virulence factors of methicillin-sensitive and -resistant S. aureus (MSSA and MRSA) that may influence host colonization and progression to VAT and VAP. ⋯ MSSA strains with strong blood agar hemolysis and high α-hemolysin activity are markers for VAP, but not VAT, and might be considered in differential diagnosis and initiation of therapy.
-
Am. J. Respir. Crit. Care Med. · Nov 2014
Targeting MARCKS Phosphorylation Site Domain in Lung Cancer: Mechanisms and Therapeutic Implications.
Phosphorylation of myristoylated alanine-rich C kinase substrate (phospho-MARCKS) at the phosphorylation site domain (PSD) is crucial for mucus granule secretion and cell motility, but little is known concerning its function in lung cancer. ⋯ These results suggest a key role for MARCKS PSD in cancer disease and provide a unique strategy for inhibiting the activity of MARCKS PSD as a treatment for lung cancer.
-
Lung cancer is a common form of cancer. There are things you can do to lower your risk of lung cancer. Stop smoking tobacco. Ask your health care provider for help in quitting, including use of medicines to help with nicotine dependence. discuss with your healthcare provider,what you are taking or doing to decrease your risk for lung cancer